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Abstract
Background: Observational studies have reported higher mortality among older adults treated with first-generation
antipsychotics (FGAs) versus second-generation antipsychotics (SGAs). A few studies examined risk for medical events,
including stroke, ventricular arrhythmia, venous thromboembolism, myocardial infarction, pneumonia, and hip fracture.
Objectives: 1) Review robust epidemiologic evidence comparing mortality and medical event risk between FGAs and SGAs
in older adults; 2) Quantify how much these medical events explain the observed mortality difference between FGAs and
SGAs.
Data sources: Pubmed and Science Citation Index.
Study eligibility criteria, participants, and interventions: Studies of antipsychotic users that: 1) evaluated mortality or
medical events specified above; 2) restricted to populations with a mean age of 65 years or older 3) compared FGAs to
SGAs, or both to a non-user group; (4) employed a ‘‘new user’’ design; (5) adjusted for confounders assessed prior to
antipsychotic initiation; (6) and did not require survival after antipsychotic initiation. A separate search was performed for
mortality estimates associated with the specified medical events.
Study appraisal and synthesis methods: For each medical event, we used a non-parametric model to estimate lower and
upper bounds for the proportion of the mortality difference—comparing FGAs to SGAs—mediated by their difference in
risk for the medical event.
Results: We provide a brief, updated summary of the included studies and the biological plausibility of these mechanisms.
Of the 1122 unique citations retrieved, we reviewed 20 observational cohort studies that reported 28 associations. We
identified hip fracture, stroke, myocardial infarction, and ventricular arrhythmias as potential intermediaries on the causal
pathway from antipsychotic type to death. However, these events did not appear to explain the entire mortality difference.
Conclusions: The current literature suggests that hip fracture, stroke, myocardial infarction, and ventricular arrhythmias
partially explain the mortality difference between SGAs and FGAs.
Citation: Jackson JW, Schneeweiss S, VanderWeele TJ, Blacker D (2014) Quantifying the Role of Adverse Events in the Mortality Difference between First and
Second-Generation Antipsychotics in Older Adults: Systematic Review and Meta-Synthesis. PLoS ONE 9(8): e105376. doi:10.1371/journal.pone.0105376
Editor: James M. Wright, University of British Columbia, Canada
Received March 10, 2014; Accepted July 23, 2014; Published August 20, 2014
Copyright:  2014 Jackson et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. The data are available within the manuscript
(tables 2 and 3) and in the supporting information (File S8).
Funding: John W. Jackson was supported by NIMH Training Grant in Training in Psychiatric Genetics and Translational Research (T32 MH017119) and the Horace
W. Goldsmith Fellowship at Harvard University. Sebastian Schneeweiss had no relevant funding. Tyler J. VanderWeele: NIH R01 ES 0178876. Deborah Blacker was
supported by NIA P50 AG005134. The funders had no role in the motivation for the study or the study design, data collection and analysis, interpretationo f
results, decision to publish, or preparation of the manuscript.
Competing Interests: SS is the primary investigator of unrelated research grants from Pfizer, Novartis, and Boehringer Ingelheim; the funders of these unrelated
grants had no bearing on the conception, design, conduct, interpretation or reporting of this study. There are no other relationships or activities that could
appear to have influenced the submitted work. There are no patents, products in development or marketed products to declare. This does not alter the authors’
adherence to all the PLOS ONE policies on sharing data and materials.
* Email: john.jackson@mail.harvard.edu
PLOS ONE | www.plosone.org 1 August 2014 | Volume 9 | Issue 8 | e105376Introduction
In 2008, nearly 3 million U.S. adults age 65 or older received
prescriptions for antipsychotic medications, 63% of which
involved off-label use not approved by the U.S. Food and Drug
Administration (FDA) [1]. One common form of such off-label
use targets agitation, aggressiveness, and psychosis in dementia
patients, which can disrupt medical and institutional care. The
decision to treat older adults with an antipsychotic involves a
careful trade-off between clinical benefit and risk for serious
adverse events [2]. In randomized controlled trials of dementia
patients, second-generation antipsychotic agents (SGAs) in-
creased mortality by as much as 54% over placebo in the first
10–12 weeks following initiation [3], leading the FDA in 2005 to
issue Black Box warnings about their excess mortality in 2005.
Subsequent observational studies demonstrated even higher
mortality during the first 24 weeks) after initiation with first-
generation agents (FGAs), leading to Black Box warnings for
FGAs in 2008. While SGAs currently represent the vast majority
of off-label use [1], FGAs represent two to 20% of the
antipsychotics prescribed in U.S. nursing homes, a variation
that may be driven by differences in institutional prescribing
culture and the lower cost of FGAs [4]. As of 2008, all FGAs
approved for use in the U.S. were available as generics and cost
$9–$26 per prescription, whereas only two of the seven approved
SGAs were available as generics and cost $85–$345 per
prescription [1].
It is not clear why FGAs increase mortality more than SGAs
in older adults soon after they begin therapy. Randomized
efficacy and so-called pragmatic or effectiveness trials are
usually not designed to answer this question. Observational
studies reported higher mortality with FGAs for cerebrovas-
cular and respiratory causes [5,6], but these categories are
broad and may suffer from misclassification [7–9]. Other
studies have investigated the association between antipsychotic
type (FGA versus SGA) and the risk of medical events, such as
stroke, ventricular arrhythmia, venous thromboembolism,
myocardial infarction, hip fracture, and pneumonia [10–18].
It is unclear from these studies’ relative risk estimates alone
which medical events are major contributors to the mortality
difference between FGAs and SGAs. Furthermore, recent
systematic reviews of these studies share this same limitation
and they have typically been limited to one medical event [19–
27].
To better understand differences in FGA and SGA related
mortality in older adults, we sought to make two contributions
to the literature. First, we provide an updated, systematic review
of the epidemiologic evidence comparing FGA and SGA risk
among older adults for mortality, stroke, ventricular arrhyth-
mia, venous thromboembolism, myocardial infarction, hip
fracture, and pneumonia. Unlike previous reviews that com-
pared the risk for various medical events between FGAs and
SGAs, we only included studies whose design and analysis
choices were relevant for evaluating short-term effects of
medications. Second, we used epidemiologic data from the
included studies, along with published mortality rates, to
quantify how much of the differential mortality between FGAs
and SGAs is potentially mediated by their differences in risk for
these medical events. Such data goes beyond describing the
relative risk for medical events to quantitatively consider their
frequency and lethality, which may be helpful when updating
monitoring guidelines.
Methods
Systematic review of the relationship between type of
antipsychotic use (FGA versus SGA) and risk of mortality
or medical events
We report this systematic review according to the standards
outlined in the PRISMA statement [28] (see Checklist S1). The
design of this study evolved from a narrative review to a systematic
and quantitative meta-synthesis of data from various sources,
which is reported here. The meta-synthesis aimed to explain
mortality differences at six-months to remain consistent with
previous literature (nine out of the 12 identified studies reporting
mortality data did so for six months follow-up; five studies
evaluated 40 days or less follow-up, and two examined mortality
after one year of follow-up). Further detail on the rationale,
extracted data, lists of obtained studies, and bias analyses are
provided in the appendix (File S3, S5, S6, and S7).
Search. We searched Pubmed through October 9, 2012 for
epidemiologic studies reporting the risk of mortality, stroke,
ventricular arrhythmias, sudden cardiac death, venous thrombo-
embolism, myocardial infarction, pneumonia, and hip fracture in
older antipsychotic users. These events were chosen apriori
through an initial review of the literature. Our final search
strategy included free-text and controlled vocabulary terms (e.g.
Medical Subject Headings) for these topics, their synonyms,
abbreviations, and alternate spellings (see File S1).
Inclusion and exclusion criteria. For this review, our
inclusion criteria applied to studies evaluating the risk for medical
events in FGA and SGA users. Our search strategy included
finding comparative randomized trials, but we did not find any
that reported on the medical events of interest as an outcome
(listed in criterion #1). Thus, we formulated criteria to reduce the
potential for bias in observational studies’ estimates of the
relationship between antipsychotic type (FGA versus SGA) and
mortality or medical events, and included observational studies
with the following characteristics: (1) evaluated antipsychotic users’
risk of mortality or the following medical events: stroke, ventricular
arrhythmia or sudden cardiac death, venous thromboembolism,
pneumonia, or hip fracture (2) directly compared FGAs to SGAs
or compared both to a non-user reference group; (3) the mean age
of the study population was 65 or greater or age-stratified results—
absolute rates or relative risks—were provided for adults over age
65; (4) the study sample was restricted to ‘‘new users’’ of
antipsychotic medications or required a washout-period of no
use prior to cohort entry; (5) adjusted for potential confounders
that were assessed prior to antipsychotic initiation; (6) and did not
require a minimum period of survival after antipsychotic initiation
for inclusion in the analysis. We required new-user designs because
prior studies demonstrate that the mortality hazard is highest
immediately after antipsychotic initiation and decreases thereafter
[29]. For the same reason, we excluded studies that required a
minimum period of survival after antipsychotic initiation for
cohort entry. We only considered studies where covariates were
assessed prior to antipsychotic initiation because adjusting for
subsequent changes in health does not control for confounding
and may increase bias [30]. The rationale for these criteria is
discussed further in the appendix (see File S3).
Selection process. We reviewed the titles and abstracts of
articles retrieved from Pubmed and selected primary research
articles that met criterion 1. From those articles that then met
criterion 2 and were published in English, we extracted
information about their study population, design, outcome
assessment and occurrence, and adjusted results. To locate
additional articles for data extraction, Science Citation Index
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cited by these articles (and those cited by relevant review articles
identified earlier during the selection process). Multiple studies
reporting results from the same administrative records were
included when differences in study design had potential for
describing mortality or medical event risk in clinically relevant
subgroups (e.g. nursing home and dementia), populations (e.g.
veterans), for use over different calendar periods or length of
follow-up, or when the analyses adjusted for different sets of
potential confounders. The studies that met criteria 3 through 6
were included in our review (see Figure 1 for flowchart). A list of
the excluded articles is provided for each medical event in the
appendix (see File S7). The article selection process and data
extraction were carried out by JWJ.
Estimation of mortality rates for medical events
To obtain estimates of six-month mortality associated with each
medical event, we also searched Pubmed for articles reporting the
pre-hospital, in-hospital, and/or post-discharge mortality (for
follow-up of one year or less) associated with stroke, ventricular
arrhythmia, acute myocardial infarction, venous thromboembo-
lism, hip fracture, and pneumonia. When possible, we chose
review articles that summarized the evidence on mortality for the
medical event, and otherwise chose recently published articles with
the broadest possible study population in the appropriate age
range, and avoided those that focused on a specific disease group
or clinical profile. None of these articles provided enough data to
precisely calculate the six-month mortality due to the medical
event for persons in this age range; several studies were not limited
to persons over age 65, did not provide rates for pre-hospital
mortality, reported a wide range of estimates, or only reported
mortality rates after discharge from an inpatient stay. We chose a
plausible estimate halfway between the total mortality for the given
medical event at three months and one year, when available.
When the mortality was reported separately for medical event
subtypes, we took a weighted average according to the frequency
of the medical event subtypes. If the studies included persons
younger than age 65 or did not report out-of-hospital deaths, we
chose the total mortality at one year. If a range for six-month
mortality was reported, we chose a plausible estimate near the
upper bound (in the section that follows, this choice serves to
provide an upper bound for the proportion mediated). Using these
approaches, we made our best approximation to the nearest 5%
on the risk scale.
To obtain estimates for the mortality among persons not
experiencing a particular medical event, we estimated the six-
month mortality as half the annual age-standardized mortality
among persons aged 65 years or older from mortality tables
published by the U.S. National Center for Health Statistics [31].
Synthesizing the evidence for the contribution of
medical events to differences in mortality between FGA
and SGA users
We calculated the difference in mortality, comparing FGAs to
SGAs, mediated by their difference in risk for a particular medical
event (stroke, for example) after antipsychotic initiation using the
following model [32]:
X
m fP½Y~1DM~m |(P½M~mDA~1 {P½M~mDA~0 )g
where A represents the type of antipsychotic initiated {1=FGA,
0=SGA}, M represents the occurrence of the medical event after
antipsychotic initiation {1=occurs, 0=does not occur}, and Y
represents mortality during six months follow-up {1=death,
0=survival} [33]. This model projects the difference in mortality
between FGA and SGA users who do and do not experience the
medical event after antipsychotic initiation. To obtain the
proportion of the mortality difference that is mediated by the
medical event, we divided this quantity by the overall difference in
mortality, P½Y~1DA~1 {P½Y~1DA~0 . The risk of the medical
event in SGA users, P½M~1DA~0 , was calculated from the
included studies as the average medical event rate (among SGAs)
per 50 person-years to approximate six-month risk; most of these
rates were originally reported in units of 100 or 1000 person-years.
Similarly P½M~1DA~1  represents the average medical event
rate among FGAs and was calculated as the product between the
average medical event rate among SGAs and the average adjusted
six-month relative risk for the medical event comparing FGAs and
SGAs (see File S4 for more detail). P½Y~1DM~1  represents the
six-month mortality given the medical event occurs, and
P½Y~1DM~0  is the six-month mortality given the medical event
does not occur. P½Y~1DA~1 {P½Y~1DA~0  was taken as the
smallest difference in mortality comparing FGAs to SGAs from
studies that reported this quantity (to provide an upper bound for
the proportion mediated). Examining the model, we see that the
projected mortality due to the medical event (and thus the
proportion mediated) depend on the absolute occurrence of the
medical event among SGAs, the difference in risk for the medical
event between FGAs and SGAs, and the difference in mortality for
those who do and do not experience the medical event. The
projected mortality difference for a given medical event (and the
proportion mediated) uses summary data from the reviewed
studies and published mortality data (a table describing the model
components, source data and populations used to estimate them is
provided in the appendix (see File S4). In this application, the
model requires an assumption that the estimates for excess
mortality P½Y~1DM~1 {P½Y~1DM~0 , which are based on
older adults in clinical and population studies, apply to older adults
treated with antipsychotics. We address the implications of this
and other limitations in the Discussion.
Bounds and bias analysis
The studies that yield data on the medical event rate
P½M~1DA~a  rely on diagnostic records in claims data which
typically have poor sensitivity. Also, the six-month mortality
estimates were interpolated from pre-hospital, 30-day and one-
year estimates in the published literature. These values were used
to obtain point-estimates for the proportion mediated. To provide
bounds that reflect these potential sources of error, we re-
estimated the proportion mediated by applying plausible values for
the sensitivity of diagnostic algorithms used across studies. We
arbitrarily chose a sensitivity of 0.9 for hip fracture because it
requires hospitalization and should be well-captured in claims
data, 0.2 for ventricular arrhythmia because it often results in
sudden death before hospitalization is possible, and 0.5 for other
medical events that can lead to pre-hospital death (e.g. stroke and
myocardial infarction). We also incorporated plausible minimum
and maximum values for excess mortality. These were taken
directly as the ranges for six-month mortality reported in the
source studies; when these were not available we calculated the
maximum plausible value for excess mortality as the one-year
medical event mortality minus the 30-day general population
mortality, and calculated the minimum value as the 30-day
medical event mortality minus the one-year general population
mortality. We also carried out formal bias analyses to further
examine how more extreme bias scenarios would affect the
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our analysis using an alternate method that calculates the
proportion mediated within each study and averages across these
results. Assumptions, estimation procedures, and results for these
bias analyses are provided in the appendix (see File S5 and S6).
The lower and upper bounds accounting for potential biases are
reported along with point estimates; note that because the bounds
take into account poor diagnostic sensitivity while the point
estimates do not, in some cases this will result in the lower bound
exceeding the point estimate.
Review of epidemiologic evidence and biological
plausibility
For mortality, we summarized the absolute and relative
difference in mortality reported by the included studies. For each
medical event, we first present the proportion of the mortality
difference explained, followed by a brief review of the epidemi-
ologic evidence and biological plausibility. Because our review
sought to understand which medical events ultimately contribute
to mortality soon after starting an antipsychotic, we focused on the
first six months after antipsychotic initiation.
Results
Search
We retrieved 1122 unique articles from Pubmed, 63 of which
compared the risk of the medical events of interest in FGAs and
SGAs. Of these, 20 articles met all inclusion criteria and reported
28 associations between antipsychotic type, mortality, or medical
events (Figure 1 and Table 1). These studies were carried out in
six distinct data sources from U.S. Medicare and Medicaid, the
U.S. and Australian Veterans Affairs health systems, Canadian
administrative health records from Ontario and British Columbia,
administrative data from a large regional hospital in Hong-Kong,
and primary care records from Italy. A list of included and
excluded citations for each medical event is provided in the
appendix (See File S7).
Overall summary of results
Among the included studies, we found higher mortality for
FGAs than SGAs in the first six months after starting antipsychotic
therapy (average relative risk=1.4; average risk difference=4.3%,
ranging from 2.5% to 7.3% in samples containing community-
dwelling and long-term care residents). Table 2 describes the
characteristics of each included study: the study population,
design, mortality and medical event rates, and relative risks
comparing FGAs to SGAs. Table 3 presents the values (obtained
by averaging across study-level data) used to estimate the projected
mortality difference for each medical event. These projections
were divided by the smallest observed total effect (2.5%) to obtain
the proportion mediated by each medical event (so that the
proportion mediated estimates reflect an upper limit absent other
biases; see File S6 for results using the largest observed total effect
(7.3%). Figure 2 depicts the causal pathway from antipsychotic
type to mortality, showing the intermediate medical events for
which FGAs carry greater risk than SGAs. Based on our model, up
to 6.7% of the higher mortality for FGAs was due to stroke, 6.6%
to hip fracture, 3.5% to myocardial infarction, and 0.9% to
ventricular arrhythmia (17.4% combined). The lower and upper
bounds that adjust for poor diagnostic sensitivity and other
potential biases were 7.4% and 18.9% for stroke, 1.3% and 9.2%
for hip fracture, 4.2% and 9.5% for myocardial infarction, and
3.9% and 4.8% for ventricular arrhythmia (16.8% and 42.4%
combined); the lower bounds are higher than the point estimate
because poor sensitivity of diagnostic algorithms leads to
downwards bias. With the exception of ventricular arrhythmia,
these bounds would be much wider in cases of extreme bias (see
File S5 and S6). In the following sections we review the
epidemiologic evidence for the differential mortality between
FGAs and SGAs, the biological plausibility and differential risk for
each medical event, and the mortality associated with each
medical event.
Mortality
Epidemiology. Of the 20 included studies, 12 investigated
mortality among antipsychotic users. Of these, 11 reported higher
all-cause or non-cancer mortality for FGAs than SGAs, appearing
as early as 30 days after antipsychotic initiation and lasting at least
six months. In retrospective cohort studies of older community-
dwelling adults, the hazard ratio was approximately 1.55 in the
first 30 days after antipsychotic initiation, and ranged from 1.27 to
1.37 at six months [29,34,35] (Table 2). The relationship was
more pronounced for doses above the median (HR=1.67 to 1.73;
median doses were unreported) and was attenuated for doses
below the median (HR=1.14 to 1.23). The corresponding
absolute differences in six-month mortality varied from 7.3% (a
statewide study in the mid-Atlantic U.S. [34]) to 2.5% (two
province-wide studies in Canada [29,35]), and a nationwide study
of Australian Veterans Affairs beneficiaries reported a 10.6%
difference in one year mortality [36]. While population differences
in SGA-related mortality may explain these heterogeneous risk
differences and relative risks [37], these studies consistently
demonstrated a dose-dependent increase in mortality for FGAs
early after initiation, lasting for at least six months in older
community-dwelling adults.
Some analyses were restricted to dementia patients in the U.S.
[34] or Canada [29,35] and reported similar elevations in six-
month mortality for FGAs compared to SGAs (HR=1.23 to 1.29).
One study of U.S. nursing home residents found elevations with
FGAs only among patients with mostly mixed and vascular
dementia [38], suggesting that the effect may be limited to a group
of patients at elevated risk for cerebrovascular and cardiovascular
disorders. Studies of U.S. veterans found higher mortality for
haloperidol at 30 days [39] and 180 days [40], as compared to
specific SGAs, while another study of U.S. veterans found no
difference in mortality at one year follow up [41]. These results
suggest that the excess mortality among dementia patients may be
limited to the first six months after antipsychotic initiation.
Claims-based studies of antipsychotics have been criticized for
their inability to adjust for important determinants of antipsychotic
use that predict mortality in older adults—namely dementia
severity, hallucinations, and delirium. Studies of U.S. nursing
home residents also adjusted for measures of cognitive and
functional decline as captured by federally mandated clinical
assessments. Results from these studies [17,38,42,43]—and others
that further adjusted for facility-level characteristics [6,17]—were
similar to those conducted in community-based populations in
terms of magnitude, timing, and dose-dependency [44]. A clinical
study using validated measures of cognitive function and dementia
symptoms found higher mortality with FGA use among nursing
home residents, but not community-dwelling residents [45].
Psychoses, though, were found to strongly predict mortality in
both samples. Confounding by delirium could be driven by the
predominant use of haloperidol to treat agitation among intensive
care unit patients with delirium [46], who have elevated six-month
mortality rates of six-month mortality [47]. Hospital medication
use is often not captured in claims data so some apparent new
users may have in fact initiated haloperidol for delirium during an
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clinical or claims data, many of the studies reviewed here likely
suffer from some degree of residual bias.
In sum, the evidence for elevated mortality in FGA users
compared to SGA users is consistent across several national and
clinical populations. Several strategies have been used to adjust for
potential confounders and most of these results signal higher risk
among FGA users, yet residual and unmeasured confounding
cannot be completely excluded as alternate explanations. We now
discuss the epidemiologic evidence for explaining this observed
difference in mortality in terms of potential intermediate medical
events.
Stroke
Overview. From 2004 to 2012, 16 studies investigated the
risk of stroke in FGA and SGA users, but only six met our
inclusion criteria. Their results support higher stroke risk with
FGAs than SGAs, but only within the first months after
antipsychotic initiation (Table 2; HR=1.03 to 1.91). The average
incidence rate per 100 persons over six months among SGA users
was 2.5, and among FGA users it was calculated to be 3.5 after
applying the average relative risk for stroke (RR=1.4). Assuming
that the excess mortality for those who experience stroke after
antipsychotic use is 17.8%, stroke may explain up to 6.7% of the
mortality difference between FGAs and SGAs (Figure 2). The
proportion mediated would be 7.4% if we expected poor
sensitivity (Sn=0.5) and a lower excess mortality of 10.0%; it
would be 18.9% for the same sensitivity but a higher excess
mortality of 26.0%.
Epidemiology. Six studies compared the risk for cerebrovas-
cular events in populations with varying degrees of pre-existing
cerebrovascular disease and duration of follow-up. Wang et al.
followed low-income, community-dwelling older adults for 120
days after antipsychotic initiation [13] and reported a slightly
higher risk of cerebrovascular events for FGAs than SGAs after 30
days (HR=1.08; 95%CI 0.99 to 1.18) and through the end of
follow-up (HR=1.09; 95%CI 1.02 to 1.16). Finkel et al. followed
Medicaid beneficiaries with dementia for three months and found
higher risk for haloperidol compared to risperidone [10]
(HR=1.91; 95%CI 1.02 to 3.60). Another study followed older
Medicaid beneficiaries for an average of three months and found
higher risk of stroke with some FGAs as compared to SGAs; the
risk was higher for phenothiazines (HR=2.34; 95%CI 1.01 to
5.41) but not butyrophenones (HR=1.44; 95%CI 0.55 to 3.76)
[14]. Other studies followed patients for six months or longer and
reported contrasting results. A study of nursing home residents
found lower risk of stroke or transient ischemic attack for FGAs
compared to SGAs (HR=0.81; 95%CI 0.65 to 1.01) [18]. Gill
et al. followed patients with dementia for an average of eight
months and found no difference in risk [11] (HR=0.99; 95%CI
0.79 to 1.23) even among high-risk subgroups defined by history of
stroke or long-term care residence. A study based in Hong Kong
followed dementia patients for an average of 2.4 years and also
found no difference in risk [16] (HR=0.93; 95%CI 0.52 to 1.67).
These results may be explained by these studies’ longer periods of
follow-up, particularly if high-risk FGA patients experience stroke
only during the first few months after antipsychotic initiation or if
such patients were more likely to discontinue or switch their
antipsychotic medication, which were both treated as censoring
events in these analyses.
Biological plausibility. While the mechanism of antipsy-
chotic-induced stroke is unclear, a recently proposed model
postulated that antipsychotics could trigger cerebrovascular events
in older adults with pre-existing medical comorbidities and
concomitant medication use [21]. This is consistent with results
from a recent case-case-time-control study of antipsychotic use and
stroke in older adults [48], where cases essentially served as their
own controls. FGAs, particularly haloperidol, the most widely used
FGA, were associated with acute movement disorders that began
soon after initiation. These extrapyramidal side-effects, as well as
sedation by low-potency FGAs such as chlorpromazine, increase
immobility, which can lead to or might exacerbate pre-existing
cases of venous thromboembolism. Low-potency FGAs can also
induce orthostatic hypotension, although it can occur with SGAs
as well. Both of these complications can cause stroke, which is a
leading cause of death.
Mortality associated with stroke. Based on the following
data, we assumed that 20% of older adults who experience a stroke
die within six months based on the following data: 80 to 90% of
strokes are ischemic, and a study of patients hospitalized for
ischemic stroke estimated their mortality as 7.4% within 30 days,
11.4% within 90 days, and 19.1% within one year. The
corresponding proportions for hemorrhagic stroke were 18.8%,
24.6% and 31.8% [49]. Very little data on sudden death in
ischemic stroke exists [50], but in the case of hemorrhagic stroke,
12% die before admission.
Ventricular arrhythmia
Overview. Six studies investigated the risk for sudden cardiac
death in FGA and SGA users. Of these, two met our inclusion
criteria. These studies suggest that the excess risk for ventricular
arrhythmias for FGAs compared to SGAs is limited to older, sicker
populations during the first weeks of follow-up (Table 2;
HR=1.20). Similarly, FGAs and SGAs appear to increase the
risk for ventricular arrhythmia in younger, healthier community
dwelling patients followed for longer periods. The average
incidence rate per 100 persons over six months among SGA users
was 0.24, and among FGA users it was calculated to be 0.26 after
applying the average relative risk for ventricular arrhythmia
(RR=1.1). Assuming that the excess mortality for those who
experience ventricular arrhythmia after antipsychotic use is
87.8%, ventricular arrhythmia may explain up to 0.9% of the
mortality difference between FGAs and SGAs (Figure 2). The
proportion mediated would be 3.9% if we expected very poor
sensitivity (Sn=0.2) and a lower excess mortality of 81%; it would
be 4.8% for the same sensitivity but a much higher excess
mortality of 99.6%.
Epidemiology. The risk of out-of-hospital sudden cardiac
death was investigated by Ray et al. in a retrospective cohort of
non-psychotic, low-income persons with no history of prior
cardiovascular disease [15]. This younger cohort (mean age
45.7) was followed for an average of two years and the results
showed similar dose-dependent elevations in risk for current use of
both FGAs (HR=1.74; 95%CI 1.14 to 2.67) and SGAs
(HR=1.86; 95%CI 1.35 to 2.57) compared to non-use. Wang
et al. investigated the risk of hospitalization for ventricular
arrhythmia in a cohort of older Medicare beneficiaries and found
higher risk for FGAs than SGAs but only within the first 30 days of
follow up [13] (HR=1.20; 95%CI 1.03 to 1.39). By 120 days of
follow up, the effect had decreased and was no longer statistically
significant (HR=1.06; 95%CI 0.96 to 1.17).
Biological plausibility. FGAs such as thioridazine, pimo-
zide, haloperidol, and droperidol are known for their dose-
dependent risk of QT prolongation through blockage of potassium
ion channels in cardiac tissue; ziprasidone is the only SGA
associated with QT prolongation. In rare cases, QT prolongation
above 450 msec increases the likelihood for a polymorphic
ventricular arrhythmia known as Torsades de Pointes (TdP) [51],
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cardiac death. The risk is higher among older patients with pre-
existing cardiovascular disease [52].
Mortality associated with ventricular arrhythmia. Based
on the following data, we assumed that 90% of older adults who
experience a ventricular arrhythmia die within six months based
on the following data: 80% percent of cardiac arrest cases occur in
the community, where chances for survival are extremely low; one
study estimated an overall survival of 6% [53]; for inpatients, the
survival ranges from 5 to 35% [54].
Venous thromboembolism
Overview. From 2005 to 2012, seven studies investigated the
risk of venous thromboembolism (VTE) or pulmonary embolism
(PE) in FGAs and SGAs. Of these, one met our inclusion criteria
and reported higher VTE/PE risk for SGAs in the first six months
after antipsychotic initiation (Table 2; HR=0.5). The average
incidence rate per 100 persons over six months among SGA users
was 0.62, and among FGA users it was calculated to be 0.31, given
this reported relative risk. Assuming that the excess mortality for
those who experience VTE/PE after antipsychotic use is 13.8%,
then the amount of the mortality difference between FGAs and
SGAs explained by VTE/PE may be as high as 22.2%. Thus,
VTE/PE does not appear to explain any of the higher mortality
among FGAs as compared to SGAs (Figure 2).
Epidemiology. A retrospective cohort study of older nursing
home residents assessed VTE risk over six months of follow-up
after antipsychotic initiation [12]. Compared to non-users, SGAs
showed nearly double the VTE risk in non-users (HR=2.01;
95%CI 1.50 to 2.70) while FGAs showed no difference
(HR=1.02; 95%CI 0.67 to 1.55), even among low- and high-
risk subgroups. While residual confounding cannot be ruled out as
a possible explanation, these subgroup analyses suggest that strong
confounding by disease severity or indication are unlikely.
Biological plausibility. The mechanism for antipsychotic-
induced VTE—in particular why the risk may differ between
FGAs and SGAs—is not known, but it may involve sedation and
immobility in low-potency FGA users, increased weight gain and
its sequale in SGA users, or other risk factors such as altered
anticardiolipin antibody levels, fibrinolytic activity, or platelet
aggregation [55]. VTE often begins as a deep vein thrombosis
(DVT), which can be lethal when it leads to PE. Among older
adults, PE occurs in a sizable number of VTE cases in both
hospital and community populations [56].
Mortality associated with venous thromboembo-
lism. Based on the following data, we assumed that 15% of
older adults who experience a VTE die within six months based on
the following data: a study of patients hospitalized for their first
VTE estimated the case mortality as 3.6% by 30 days and 12.6%
by one year among those without cancer [57]. Nearly one-quarter
of those who develop PE present with sudden death and another
quarter die within a year after discharge [58]. In the study
reporting on VTE risk among antipsychotic users, 78% were
diagnosed with DVT and 22% with PE.
Myocardial infarction
Overview. We found five articles published from 2006 to
2012 that investigated myocardial infarction (MI) risk for FGAs
and SGAs, two of which met our inclusion criteria. These studies
are consistent with higher risk for FGAs than SGAs (Table 2;
HR=1.16 to 1.23). The average incidence rate per 100 persons
over six months among SGA users was 1.0, and among FGA users
it was calculated to be 1.2 after applying the average relative risk
for MI (RR=1.2). Assuming that the excess mortality for those
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PLOS ONE | www.plosone.org 10 August 2014 | Volume 9 | Issue 8 | e105376who experience MI after antipsychotic use is 42.8%, then the
proportion of the mortality difference between FGAs and SGAs
explained by MI may be as high as 3.5% (Figure 2). The
proportion mediated would be 4.2% if we expected poor
sensitivity (Sn=0.5) and a much lower excess mortality of
26.0%; it would be 9.5% for the same sensitivity but a much
higher excess mortality of 59.6%.
Epidemiology. Two cohort studies have evaluated the risk of
MI in both FGAs and SGAs. The Wang et al. study described
earlier found a higher risk for FGA users at 120 days after
antipsychotic initiation (HR=1.16; 95%CI 0.91 to 1.48), but no
difference in risk at 30 or 60 days [13]. The Huybrechts et al.
study of nursing home residents also assessed the risk of
hospitalization for MI at six months after initiation and found
higher risk for FGAs compared to SGAs (HR=1.23; 95%CI 0.82
Table 3. Medical event occurrence, association with antipsychotic type (FGA vs. SGA), and difference in mortality between FGAs
and SGAs due to their difference in risk for the medical event.
Event
Average Medical Event
Rate and Range* among
SGA users (per 100 PY
{)
Average Medical Event
Relative Risk and Range*
(FGA vs. SGA users)
Six-month
Mortality for the
Medical Event
Difference in mortality due to differences
in medical event risk between FGA and
SGA users (lower bound, upper bound
accounting for potential bias)**
Stroke 4.7 (2.6 to 9.2) 1.4 (0.81 to 1.91) 20% 0.17% (0.18 to 0.47)
Ventricular Arrhythmia 0.48
` 1.1
` 90% 0.02% (0.10 to 0.12)
Venous Thromboembolism 1.2
` 0.5
` 15% 20.06% (------- to -------)
Myocardial Infarction 2.0
` 1.2 (1.16 to 1.23) 45% 0.09% (0.10 to 0.24)
Hip Fracture 6.2 (3.8 to 8.5) 1.3 (1.27 to 1.39) 20% 0.16% (0.03 to 0.23)
Pneumonia 4.8 (1.9 to 7.6) 1.0
1 (0.84 to 1.28) 20% 0.00% (------- to -------)
*arithmetic average (minimum, maximum) of reported estimates from included studies (as described in the methods section).
{Rates here are shown in units of 100 person-years; in calculations and in the text they were scaled to units of 50 person-years to approximate six-month risk.
`Only 1 study contributed to these rounded estimates (RR=1.06 for ventricular arrhythmia and RR=0.51 for venous thromboembolism).
1Although the average was 1.04, the confidence intervals for the contributing estimates were wide and evenly distributed about the null.
**Estimate, lower and upper bounds for the projected mortality difference (i.e. without denominator of total effect. Bounds were only estimated for medical events that
appeared to explain the higher mortality for FGAs i.e. Relative Risk.1).
doi:10.1371/journal.pone.0105376.t003
Figure 2. The causal pathway from antipsychotic type to mortality through medical events. The average medical event rates (per 100
person-years) were 4.7 for stroke, 0.48 for ventricular arrhythmia, 1.2 for venous thromboembolism, 2.0 for myocardial infarction, 6.2 for hip fracture,
and 4.8 for pneumonia. In calculations they were scaled to units of 50-person years to approximate six-month risk.
doi:10.1371/journal.pone.0105376.g002
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rate of MI [18], which was low (2.0 cases per 100 person-years), so
there may have been insufficient power to provide a more precise
estimate.
Biological plausibility. The mechanisms by which antipsy-
chotic use could lead to MI may involve effects on blood lipid
levels, which may exacerbate atherosclerosis, or effects on platelets
and other clotting factors leading to increased coagulability. MI is
a leading cause of death.
Mortality associated with myocardial infarction. Based
on the following data, we assumed that 45% of older adults who
experience a myocardial infarction die within six months: in a
study of older Medicare patients admitted for MI, 26.3% died
within 30 days after discharge and an additional 20% died within
the remaining year [5].
Hip fracture
Overview. From 2004 to 2012, 12 studies investigated the
association between falls or fracture risk in both FGA and SGA
users, two of which met our inclusion criteria. These studies
suggested that FGAs carry higher risk for hip fracture in nursing
home residents soon after antipsychotic initiation (Table 2;
HR=1.27 to 1.61). Because falls and fractures occur more
frequently among nursing home patients, this estimate may not
apply to the general population. Nevertheless, the average
incidence rate per 100 persons over six months among SGA users
was 2.38, and among FGA users it was 3.33 after applying the
average relative risk for hip fracture (RR=1.4) (we averaged as-
treated and intent-to-treat HR estimates reported in the same
study; see File S2). Assuming that after antipsychotic use, the
excess mortality for those who experience hip fracture is 17.8%,
then hip fracture may explain up to 6.5% of the mortality
difference between FGAs and SGAs (Figure 2). The proportion
mediated would be 1.3% if we expected poor sensitivity (Sn=0.5)
and a much lower excess mortality of 3.1%; it would be 9.2% for
the same sensitivity but a much higher excess mortality of 22.6%.
Epidemiology. Huybrechts et al. followed newly admitted
nursing home residents in British Columbia for six months and
found higher risk for FGAs than SGAs [17] (HR=1.61; 95%CI
1.03 to 2.51), following patients until they experienced a hip
fracture, died, discontinued their antipsychotic or started using an
antipsychotic from the comparison group. When analyzed using
the intention-to-treat approach, the hazard ratio was considerably
lower (HR=1.16; 95%CI 0.82 to 1.63). Another study followed
nursing home residents without major psychotic disorders or
cancer for six months and also found higher risk for FGAs
(HR=1.27; 95%CI 0.94 to 1.72) [18].
Biological plausibility. Acute extrapyramidal symptoms
occur more frequently with FGAs [59]. Dystonia, parkinsonism,
dyskinesia, and akathisia can manifest as early as the first few days
after initiation or as late as three months. Such symptoms can
cause gait disturbances and impair mobility and balance, which
are risk factors for falls (and thus fractures) in older adults [60].
Fractures increase the risk for mortality in older adults.
Mortality associated with hip fracture. Based on the
following data, we assumed that 20% of older adults who
experience a hip fracture die within six months based on the
following data: hip fracture increases mortality and 70% of the
deaths occurring in the year following fracture happen within the
first six months after injury [61]; at six months, the mortality
among hip fracture cases ranges from 7.1% to 23%. Some of this
mortality may be attributable to underlying comorbidity that
increases risk for both hip fracture and mortality.
Pneumonia
Overview. From 2004 to 2012, seven studies investigated the
risk for pneumonia in both FGAs and SGAs. The three that met
our inclusion criteria reported no differences in risk between FGAs
and SGAs within the first six months after antipsychotic initiation.
One study (Wang et al. 2007 [62]) reported lower risk in FGA
users but only after 120 days follow-up, which could indicate that
SGA users experience higher risk after three or four months
following antipsychotic initiation but the average relative risk was
null over follow-up. Taken together, these results suggest that
pneumonia does not explain any of the higher mortality in FGAs
as compared to SGAs (Figure 2).
Epidemiology. Three retrospective cohort studies evaluated
the risk of pneumonia in FGA and SGA users. The Wang et al.
study [62] of low-income older, frail, community-dwelling adults
found no difference in risk at 30 (HR=1.11; 95%CI 0.76 to 1.63)
or 60 days (HR=1.03; 95%CI 0.76 to 1.38). By 120 days the
pneumonia risk was lower for FGAs as compared to SGAs
(HR=0.84; 95%CI 0.66 to 1.05). A study of newly admitted
nursing home residents in British Columbia [17] showed no
difference in risk at six months after antipsychotic initiation
(HR=1.03; 95%CI 0.62 to 1.69). Another study followed U.S.
nursing home residents without cancer, schizophrenia, or bipolar
disorder for up to six months and also found no difference in risk
[18] (HR=1.28; 95%CI 0.87 to 1.88).
Biological plausibility. The most plausible mechanism for
possible differences in pneumonia risk for FGAs and SGAs is the
higher frequency of extrapyramidal symptoms and sedation
among FGA users. Extrapyramidal symptoms involving the
pharyngeal musculature could lead to dysphagia, and excess
sedation could lead to decreased cough-reflex, both of which are
risk factors for aspiration pneumonia in older adults [63]. Another
potential mechanism could involve altered cytokine profiles and
immune response, but the supporting evidence for this pathway is
incomplete as these studies have not comprehensively investigated
how specific antipsychotics, FGAs or SGAs, influence inflamma-
tory activity across in vivo, ex vivo, and in vitro systems [64].
Mortality associated with pneumonia. Based on the
following data, we assumed that 20% of older adults who
experience die within six months based on several lines of
evidence. An observational study of nursing home residents with
advanced dementia reported a 90-day mortality rate, after
pneumonia diagnosis, ranging from 36% to 67% depending on
the type of care received [65]; 51% of these cases had a do-not-
hospitalize order. A review of community-acquired pneumonia
reported a mortality rate of less than 1% for cases managed in
outpatient settings [66]; among the 22 to 42% of patients in
population-based studies with severe enough pneumonia to
warrant inpatient or intensive care, mortality ranged from 14 to
54%. A large study of Medicare beneficiaries hospitalized for
community-acquired pneumonia reported 11% mortality during
hospitalization and 36% mortality over six-months among those
discharged alive; at one year the total mortality was 41% [67].
Differences in pneumonia management and medical comorbidity,
especially considering end-of-life decision making for older adults,
may contribute to the wide variability in mortality among studies
of inpatient pneumonia cases.
Discussion
Main findings
We found that older adults using FGAs were at higher risk for
stroke, ventricular arrhythmia, myocardial infarction, and hip
fracture as compared to SGAs. Using the lowest estimate of 2.5%
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stroke accounted for 6.7% of this difference, hip fracture for 6.5%,
myocardial infarction for 3.5%, and ventricular arrhythmia for
0.9%. The lower and upper bounds that account for poor
diagnostic sensitivity and other potential biases are 7.4% and
18.9% for stroke, 1.4% and 9.2% for hip fracture, 4.2% and 9.5%
for myocardial infarction, and 3.9% and 4.8% for ventricular
arrhythmia. Combined, these medical events explained about one-
sixth (17%) of the mortality difference between FGAs and SGAs
(assuming independent contributions), but this value could be as
large as 42% given the limitations and uncertainties in the source
data. Pneumonia and VTE did not account for any of the
observed mortality difference. These results suggest that hip
fracture, stroke, myocardial infarction, and ventricular arrhythmia
are on the causal pathway to mortality, but that ventricular
arrhythmia plays a minor role.
Evidence gaps
Overall, our study was consistent with the findings of previous
literature reviews of medical event risk in antipsychotic users
[19,21–25]. The following may explain why the medical events we
reviewed did not explain more of the mortality difference: (1) the
magnitude of the mortality difference may be biased from residual
confounding through selective prescribing to FGA and SGA users
based on socioeconomic status or prior health conditions (2) the
difference in risk for each medical event may be similarly biased
due to residual confounding; (3) most of the reviewed studies were
performed in administrative data and used diagnostic billing
records to assess the medical events, which typically results in low
sensitivity and would underestimate the proportion mediated by a
medical event [68]. In the absence of these potential biases, the
data suggest that other medical events (e.g., bacterial infection,
respiratory failure, renal failure, or neuroleptic malignant
syndrome) may also contribute to the mortality difference.
While adequately powered randomized controlled studies
evaluating medical event risk in both FGAs and SGAs would be
ideal for characterizing the causal pathway to mortality, they are
unlikely to be conducted and are possibly unethical in this setting.
With the exception of stroke and pneumonia, we found few
observational studies whose sample size, design, and analysis were
suited to identify short-term drug effects (see inclusion criteria).
Future studies with more robust methods would provide better
evidence to characterize the risk of antipsychotic-related medical
events and contribution to mortality.
The relative contributions by medical events to mortality most
likely vary across populations with different indications, acuity,
socioeconomic status, and quality of clinical care. While the
association between antipsychotic type and mortality was charac-
terized in several populations and subgroups, the studies of
medical events were not. Among the included studies, stroke was
the only event characterized in dementia patients. The other
medical events were limited to either community-dwelling
populations or nursing home residents.
Limitations and strengths
This systematic review’s results hinge on the quality of the
included studies. Although each study reviewed adjusted for
diagnoses, health service and medication use, it is possible that the
individual studies suffered from residual or unmeasured con-
founding by risk factors for mortality or for the medical event
studied. The algorithms used to classify medical comorbidity in
administrative data, which were used by all of the included studies,
often perform poorly (i.e. subject to misclassification) and will fail
to completely control for confounding [69]. A study of commu-
nity-dwelling Medicare beneficiaries showed that unmeasured
confounding by BMI, smoking, and cognitive and functional
impairment would underestimate the association between anti-
psychotic type and mortality [44]; the relationship between
antipsychotic type and each of the medical events could be
affected in similar ways. In some of the included studies
[17,29,34], dementia, which is positively associated with increased
cardiovascular risk and mortality, was more common in SGA users
than FGA users (despite their differences in mean age). Other
potential bias may come from risk factors for medical events, such
as smoking, that independently predict mortality and are
distributed differently between the general population and patients
receiving antipsychotics. This sort of bias would distort our
estimates of excess mortality but cannot be adequately controlled
in this design. We have provided bounds and bias analyses to
reflect these sources of uncertainty in our analysis.
The model used to estimate the proportion of the mortality
difference mediated by medical events would be subject to any bias
from unmeasured or residual confounding in the individual
studies. Even in the absence of such bias, the model did not
account for population heterogeneity between the studies report-
ing rates of medical events among antipsychotic users and the
studies reporting mortality rates. In particular, the mortality rates
were calculated from studies consisting of older adults from the
general population; they may thus underestimate the expected
mortality in antipsychotic users who did (or did not) experience a
medical event. If this underestimation was more severe for those
who did not experience a medical event, the proportion mediated
would be inflated. Conversely, if this underestimation was more
severe for those who experienced the medical event, the
proportion mediated would be attenuated. If the mortality
underestimation were similar in absolute terms for those with
and without the medical event, the bias would cancel. The bounds
and bias analyses reflect these sources of uncertainty.
Although it is clear from these analyses that ventricular
arrhythmia plays a minor role, the bounds and bias analyses
portray a sizeable amount of uncertainty for other medical events,
especially in cases of extremely poor sensitivity of diagnostic
algorithms used to extract diagnostic information from claims data
(although for hip fracture this is less of a concern). Our most
plausible estimates suggest that up to 42% of the smallest observed
difference in mortality (2.5%) might be explained by these events.
However, the unadjusted mortality difference is in fact larger in
some populations (7.3%) and the corresponding upper bound
would be 15% (the proportion mortality decreased because the
projected mortality was held fixed while the overall difference in
mortality was increased in this example). On the one hand, the
large degree of unexplained mortality in either situation might
demand investigation of other unsuspected adverse events. For
instance, drug-drug interactions with antipsychotics may occur in
the elderly whose age-related changes in drug metabolism and
clearance may be exacerbated by complex medication regimens
for comorbid conditions [70]. On the other hand, our inability to
explain the mortality difference despite considering many known
risks is also consistent with hypotheses of residual and unmeasured
differences between patients who receive FGAs versus SGAs.
These limitations and uncertainty motivate a formal mediation
analysis of individual-level data, with properly measured medical
events, that would allow for confounding adjustment and would
model the relationships between antipsychotic type, medical
events, and mortality in the same dataset. Such an approach
could also be performed for relevant population subgroups and
confirmed across study populations. The current approach of
synthesizing safety data could be extended to use more sophisti-
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lower and upper bounds.
To our knowledge, our review is the first to quantify how
important various medical events are in actually explaining
mortality differences between FGAs and SGAs. Our results also
demonstrate how the relationship between serious adverse drug
events and mortality depend on their frequency, association with
exposure, and lethality. The scope of prior reviews was limited to
providing summary relative risks for the medical events and, in
most cases, included studies whose designs were not optimally
suited for assessing drug safety soon after initiation. We further
improved upon these reviews by only summarizing studies that
adjusted for measured confounders, employed a new user design,
assessed covariates prior to antipsychotic initiation (or treatment
change), and avoided selection bias and immortal person-time
bias. These design choices protect against common threats to
validity in observational studies and are recommended practice in
pharmacoepidemiology [30,71,72].
This review focused on the mortality difference between FGAs
and SGAs and, because these agents share mechanisms of action,
the results may only partially apply to mortality differences
between antipsychotic users versus non-users. To answer this
pressing question, an alternate approach could focus on explaining
the mortality difference between SGAs and placebo in clinical
trials, and perhaps overcome their lack of power through pooling
data at the individual or study level. However, this approach
would face its own limitations: many of the placebo-controlled
trials in dementia patients did not consistently report adverse
events and their enrollment criteria often limit the relevance of
their findings to patients seen in actual clinical practice [73]. The
definitive effectiveness trial that compared individual SGAs for
reducing behavioral and psychiatric symptoms in dementia lacked
a placebo arm and was not designed to detect serious adverse
events [74].
Implications for clinical practice
We found consistently higher mortality for FGAs than SGAs in
longitudinal claims-based studies. The few analyses that provided
comparative data for medical events suggest that the mortality
difference may be explained in part by stroke, hip fracture, acute
myocardial infarction, and ventricular arrhythmia. These results
emphasize the need for frequent monitoring of FGA users with
pre-existing cardiovascular morbidity and functional decline, and
that SGAs may represent safer initial options than FGAs after
alternative therapies have been exhausted. As recommended by
current treatment guidelines [2], patients started on either FGAs
or SGAs should be evaluated early and repeatedly for whether a
lower dose will suffice and whether continued use is warranted.
This recommendation is buttressed by evidence that antipsychotic
discontinuation in older adults reduces their mortality by as much
as 32% in the following year [75].
Conclusions
Our review summarized the literature on several serious adverse
events in older antipsychotics and provided important contribu-
tions. First, newly published studies on antipsychotic-related
mortality in nursing home residents that adjust for measures of
functional and cognitive decline are consistent with previous
findings. Second, despite the large body of research on antipsy-
chotic-related medical events, very few studies followed recom-
mended guidelines for reducing bias in observational studies of
therapeutics. Last, and perhaps most important, we have shown
that the published literature itself can be summarized to
quantitatively compare potential mechanisms of drug-related
mortality. Our results suggest the mortality difference between
FGAs and SGAs may involve several pathways, and each
influenced differently by the underlying medical event rate and
the rate difference between FGAs and SGAs, as well as the excess
mortality associated with the medical event. Much of the mortality
difference between FGAs and SGAs was unexplained by the
medical events included in this review. A formal mediation
analysis using individual level data would overcome some of the
limitations in our review.
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